PETS PetMed Express, Inc.

BEARISH Impact: 6/10 PRESS-RELEASE
Horizon weeks Filed Jun 2, 2026 Processed 2d 23h ago Wire GlobeNewswire
Press release: earnings
Latest settled — T+1d ⚠ clustered
PETS ▲ +2.25% at T+1d
SHORT call ✗ call lost -2.25% · α vs SPY -1.84% · entry $1.78 → $1.82
Next anchor: T+5d in 4d
Currently $1.69 · +5.06% from $1.78 entry (call sign-flipped)
Entry anchored
Jun 2, 03:59 PM ET
via Databento tick
T+1d
+2.25%
call -2.25% · α -1.84%
$1.82
settled 2d ago
T+5d
call — · α —
in 4d
T+20d
call — · α —
in 26d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

PetMed Express reported Q4 FY2026 net sales of $42.8M (-15.6% YoY) and a net loss of $4.1M ($0.19/share), narrowing from a $11.6M loss in the prior year. The company's full-year revenue fell 21.1% to $179M, with a net loss of $57.3M driven by a $26.7M goodwill impairment and $4.5M in whistleblower investigation costs. The board rejected two acquisition proposals at $4.00-$4.25/share, opting to remain independent.

Key Financial Metrics

Free Cash Flow
-$33.0M
Gross Margin
32.6%

Actionable Insight

The board's rejection of acquisition proposals at $4.00-$4.25/share removes a near-term liquidity event, while cash burn ($28.4M operating cash outflow) and declining revenue fundamentals suggest continued downside risk. Monitor for further inbound M&A interest or potential capital raise given cash runway concerns.

Key Facts

  • Q4 FY2026 net sales $42.8M, down 15.6% YoY from $50.8M
  • Full-year FY2026 net sales $179.0M, down 21.1% YoY from $227.0M
  • Q4 net loss $4.1M ($0.19/diluted share) vs $11.6M loss ($0.56) prior year
  • Full-year net loss $57.3M ($2.74/diluted share) vs $6.3M loss ($0.30) prior year
  • Full-year adjusted EBITDA -$15.4M vs +$0.7M prior year
  • Goodwill impairment charge of $26.7M recorded in Q1 FY2026
  • Board rejected two acquisition proposals at $4.00-$4.25/share, continuing as independent company
  • Cash and cash equivalents $21.4M at March 31, 2026, down from $54.7M a year ago
  • Operating cash flow -$28.4M for FY2026 vs +$4.7M prior year

Financial Impact

Revenue decline of 21.1% YoY to $179M, net loss widening to $57.3M from $6.3M, adjusted EBITDA swinging from +$0.7M to -$15.4M

revenuenet incomeadjusted EBITDAoperating cash flowcash balance

Risk Factors

  • Continued revenue decline and cash burn may necessitate equity or debt financing
  • Whistleblower investigation costs and goodwill impairment signal operational and governance issues
  • No acquisition premium materializing after board rejected proposals
  • Negative adjusted EBITDA trajectory with no near-term path to profitability

Market Snapshot

Exchange
Nasdaq
Sector
Retail-Drug Stores and Proprietary Stores
Analyst Consensus
0% bullish (6 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3305585
4 reports for PETS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PETS — sortable, filterable
Type Now
Jun 2, 2026
2d ago
8-K
BEARISH ★ 7/10
$1.78 $1.82▼ −2.25%▼ −1.84%$1.69 (+5.06%)
Jun 2, 2026
2d ago
Press Release
BEARISH ★ 6/10
$1.78 $1.82▼ −2.25%▼ −1.84%$1.69 (+5.06%)
May 29, 2026
7d ago
Press Release
NEUTRAL ★ 2/10
awaiting T+1
Apr 22, 2026
6w ago
Press Release
BULLISH ★ 7/10
$2.23 $2.29▲ +2.69%▲ +1.91%$1.69 (−24.22%)
Showing 4 of 4

US Market Status

Market Open — Closes in 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access